← Oncology Approval Tracker

FDA DECISION ·

Nypozi

filgrastim-txid · Tanvex BioPharma USA

Biosimilar approvalBiosimilarChemotherapy-related neutropenia and stem cell support
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Filgrastim biosimilar for labeled uses including reducing infection associated with chemotherapy-related febrile neutropenia, shortening neutrophil recovery after AML chemotherapy or marrow transplant, and mobilizing autologous peripheral blood progenitor cells.

LAMPGEN ANALYSIS

Why it matters

A Neupogen biosimilar adds another G-CSF product for supportive care and transplant workflows.

What research teams should watch

Standardize biosimilar naming and lot capture and check that each ordered syringe and route matches the indication.

PRIMARY RECORDS

Sources